EPx4 Raises Odds of Renal, Nerve, Hearing Harms

Multicenter outcomes study finds cisplatin dose drives toxicity differences between guideline-endorsed regimens, with kidney function decline predicting cardiovascular risk

By
Kerri Miller
February 25, 2026
5 min

MDSpire News

Objective:

To analyze the long-term health outcomes of testicular cancer survivors treated with different chemotherapy regimens, specifically comparing EPx4 and BEPx3.

Key Findings:

Patients treated with EPx4 had 1.55 times the odds of renal impairment compared to BEPx3, and BEPx4 was linked to higher odds of Raynaud phenomenon compared to EPx4.

Interpretation:

Long-term survivors of testicular cancer treated with EPx4 face increased risks of renal, nerve, and hearing complications compared to those treated with BEPx3, highlighting the need for careful long-term health management.

Limitations:

text

Conclusion:

This study highlights the comparable long-term CBM scores between EPx4 and BEPx3, but significant differences in cisplatin-related toxicities, emphasizing the need for careful monitoring of long-term health outcomes, particularly renal and neurological health.